Contribution of Gag and Protease to HIV-1 Phenotypic Drug Resistance in Pediatric Patients Failing Protease Inhibitor-Based Therapy

Antimicrobial Agents and Chemotherapy
Jennifer GiandhariLynn Morris

Abstract

Protease inhibitors (PIs) are used as a first-line regimen in HIV-1-infected children. Here we investigated the phenotypic consequences of amino acid changes in Gag and protease on lopinavir (LPV) and ritonavir (RTV) susceptibility among pediatric patients failing PI therapy. The Gag-protease from isolates from 20 HIV-1 subtype C-infected pediatric patients failing an LPV and/or RTV-based regimen was phenotyped using a nonreplicativein vitroassay. Changes in sensitivity to LPV and RTV relative to that of the matched baseline (pretherapy) sample were calculated. Gag and protease amino acid substitutions associated with PI failure were created in a reference clone by site-directed mutagenesis and assessed. Predicted phenotypes were determined using the Stanford drug resistance algorithm. Phenotypic resistance or reduced susceptibility to RTV and/or LPV was observed in isolates from 10 (50%) patients, all of whom had been treated with RTV. In most cases, this was associated with protease resistance mutations, but substitutions at Gag cleavage and noncleavage sites were also detected. Gag amino acid substitutions were also found in isolates from three patients with reduced drug susceptibilities who had wild-type protease. Site-dire...Continue Reading

References

Jan 18, 2007·PLoS Medicine·Monique NijhuisCharles A B Boucher
Jan 17, 2008·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Yuan RenHelen M McIlleron
Nov 21, 2008·The New England Journal of Medicine·Avy ViolariUNKNOWN CHER Study Team
May 2, 2009·Current Opinion in Infectious Diseases·Ravindra K GuptaDeenan Pillay
Sep 26, 2009·The Pediatric Infectious Disease Journal·Gert U van ZylWolfgang Preiser
Sep 9, 2010·JAMA : the Journal of the American Medical Association·Ashraf CoovadiaLouise Kuhn
Oct 15, 2010·The New England Journal of Medicine·Paul PalumboAvy Violari
Dec 15, 2010·Antimicrobial Agents and Chemotherapy·Chris M ParryDeenan Pillay
Oct 14, 2011·Viruses·Akbar AliCelia A Schiffer
Nov 17, 2011·Journal of the International AIDS Society·Gert U van ZylMark F Cotton
Aug 8, 2012·Retrovirology·Axel FunMonique Nijhuis
Sep 4, 2012·Nature Medicine·Daniel I S RosenbloomMartin A Nowak
Jan 11, 2013·The Pediatric Infectious Disease Journal·Catherine OrrellRobin Wood
Aug 28, 2013·The Journal of Clinical Investigation·John A Bartlett
Aug 28, 2013·The Journal of Clinical Investigation·S Alireza RabiRobert F Siliciano
Sep 12, 2013·Current Opinion in Virology·Janet D Siliciano, Robert F Siliciano
Apr 11, 2014·Journal of Virology·Madhavi KolliCelia A Schiffer
Aug 7, 2014·The Journal of Antimicrobial Chemotherapy·Katherine A SutherlandRavindra K Gupta
Oct 25, 2014·Viruses·Pinar Iyidogan, Karen S Anderson
Apr 29, 2015·AIDS Research and Human Retroviruses·Jennifer GiandhariGillian M Hunt
Jul 15, 2015·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Mireille PorterBrian Eley

❮ Previous
Next ❯

Citations

Sep 17, 2016·Journal of Tropical Pediatrics·Ragna S BoermaJob C J Calis
Feb 16, 2019·The Journal of Antimicrobial Chemotherapy·Marine PerrierCharlotte Charpentier

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.